Skip to Main Content

Advertisement

Skip Nav Destination

A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS)

Blood (2018) 132 (Supplement 1): 465.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement